Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement was noninferior to surgery for death and stroke at 1 year in a real-world ...

At 6 years, transcatheter aortic valve replacement (TAVR) appears to rival surgery for major adverse events in low-risk patients with severe aortic stenosis, but it may come at the cost of more ...

A risk model allowing cardiologists and their patients to share decision-making about undergoing surgery after transcatheter aortic valve replacement (TAVR) had received high marks for its accuracy in ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

To inform heart team and patient decision-making on valve surgery, The Society of Thoracic Surgeons (STS) has launched new risk calculators for isolated tricuspid valve repair and replacement; ...

SAN FRANCISCO -- A handful of years later, transcatheter aortic valve replacement (TAVR) still compared well against surgery in the PARTNER 3 and Evolut Low Risk trials. PARTNER 3 appeared to show a ...

High-risk surgical patients with severe aortic stenosis who underwent a transcatheter aortic valve replacement experienced higher one-year survival rates than patients who underwent traditional ...

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic valve stenosis. With proven safety and efficacy, TAVR has become a standard therapeutic alternative to surgical ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

Intermediate-risk patients who received transcatheter aortic valve replacement, known as TAVR, with the latest-generation valve fared better than patients receiving traditional surgical aortic valve ...